ClinicalTrials.gg
Enrolling by invitationNCT06588803Updated Mar 5, 2025

A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA

An observational study in Spinal Muscular Atrophy, sponsored by Hangzhou Jiayin Biotech Ltd. Enrolling by invitation at 1 site in China. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Hangzhou Jiayin Biotech Ltd · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
18
Ages
1 Month and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Muscular Atrophy, Spinal with a site in China — 6 open to participants now, 13 under way, 4 of them phase 3. Muscular Atrophy, Spinal · China.

Started
2025
with 3 others
Observational
7 of 23
2 open now
Primary completion
2030-09
later than 10 of 12 live
Registered
16th of 23
by date
Lead sponsor
2 of 23
Hangzhou Jiayin Biotech Ltd

Among the 23 studies in Muscular Atrophy, Spinal with a site in China, this one is one of 4 that started in 2025, is one of 7 observational ones, reaches primary completion later than 10 of the 12 other live ones, and was the 16th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

6 of the 23 studies in Muscular Atrophy, Spinal with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 1 Month and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Muscular Atrophy, Spinal with a site in China, or all of them as a file.
02

Study summary

An Open-label, Long-term Follow-Up Study to Evaluate the Safety and Tolerability of Gene Therapy with EXG001-307 in SMA1 patients ,who joined the parent study (EXG001-307-102)

Read the detailed description

This study plans to enroll type 1 SMA patients who have previously received EXG001-307 treatment in the parent trial EXG001-307-102 to observe the long-term safety and efficacy of gene therapy with EXG001-302.

The first year of long-term follow-up will be conducted every 3 months ; In the second year, follow-up visits will be conducted every six months, with telephone follow ups at 15 and 21 months during this period; From 3 to 5 years after gene therapy, follow up by phone every six months and follow on on site once a year.

03

Conditions studied

  • Spinal Muscular Atrophy

Keywords

  • SMA
04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Type 1 SMA patients who have previously used EXG001-307 in trial EXG001-307-102 .

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previously received treatment with EXG001-307 in trial EXG001-307-102;
  2. Parents or guardians understand the research procedure and sign the ICF; Good compliance and willingness to follow research procedures. Voluntarily participate in this clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Parents or guardians are unwilling or unable to participate in long-term follow-up studies.
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
18 participants (estimated)
Patient registry
No

Interventions

  • OtherNo intervention, only for observational studies

    No intervention, only for observational studies

06

What researchers measure

Primary outcomes

  1. long-term safety:Assess the types, severity, and incidence of serious adverse events (SAEs) and adverse events of particular concern (AESIs)

    Assess the types, severity, and incidence of serious adverse events (SAEs) and adverse events of particular concern (AESIs)

    Time frame: 4 years

Secondary outcomes

  1. Evaluate the long-term effectiveness of EXG001-307 treatment: assess the achievement of exercise milestones based on the scale

    The achievement of new milestones in the third edition of the Berry Infant and Child Development Scale (BSID-III): Doctors need to evaluate whether patients can achieve the following milestones: head control:Can children keep their heads upright for at least 3 seconds without support; sitting without assistant:Can children sit up alone for at least 5 seconds without support; standing with assistant:Can children use chairs or other convenient objects as support to stand up on their own; standing without assistant:Can the child stand alone for at least 3 seconds after the evaluator releases the child's hand; walking with assistant:Can children make coordinated and alternating stepping movements while walking; walking without assistant:Can children walk at least three steps without support, even if their gait is stiff and unstable;

    Time frame: 4 years

  2. Evaluate the long-term effectiveness of EXG001-307 treatment: evaluate event free survival rate

    Event free survival rate: The event free survival rate refers to the proportion of subjects who did not die and did not require permanent mechanical ventilation with a ventilator. Permanent mechanical ventilation refers to the need for tracheotomy to maintain ventilation in irreversible emergencies or after emergency resolution, or the need to rely on Bipap mechanical ventilation support for ≥ 16 hours per day for more than 3 consecutive weeks, or tracheal intubation for ≥ 3 weeks; Researchers evaluate patients by examining their daily use of ventilators.

    Time frame: 4 years

  3. Evaluate the immunogenicity of EXG001-307 after treatment, including measuring the titers of anti-AAV9-ADA and anti-SMN-ADA antibodies.

    After blood collection, send it to the central laboratory to complete the following antibody testing: the titers of anti-AAV9-ADA and anti-SMN-ADA antibodies (until two consecutive negative results);

    Time frame: 4 years

  4. Evaluate the distribution of viral vectors after treatment with EXG001-307: detect the level of vector genome in saliva, feces, and urine samples of subjects.

    Carrier distribution: Genomic level of carriers in saliva, urine, and fecal samples (up to two consecutive negative resultst);

    Time frame: 4 years

  5. Exploratory objective: To calculate the proportion of subjects receiving other SMA treatments during the trial period

    Calculate the proportion of subjects receiving other SMA treatments to the total number of subjects.

    Time frame: 4 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Sep 2030, 66 months later.

Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 66 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Sep 19, 2024
StartEst.
Mar 2025
Primary completionEst.
Sep 10, 2030
CompletionEst.
Dec 31, 2030
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06588803
Lead sponsor
Hangzhou Jiayin Biotech Ltd
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Mar 2025 (estimated)
Primary completion
Sep 10, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 5, 2025

Study contacts

YI WANG, Ph D.
principal investigator · Children's Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion